Survodutide
Tested in peopleIt has been tested in people, but it is not an approved medicine. The studies are usually small.
Also called BI 456906
Hits two hormone targets for weight loss and liver disease. In human trials, not approved.
Can a doctor prescribe this?
No. Pharmacies are not on record as being allowed to make this into a medicine.
The FDA has not approved this as a medicine.
Investigational. Not approved and not legal to compound.
Official status: Not on the 503A bulks list. Checked 2026-08-04.
Lab suppliers we list: 5
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
In human trials
See source wording
under the skin · weekly
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightPHASE3 · NCT06066528
“Survodutide 3.6 mg.”
See source wording
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)PHASE2 · NCT04771273
“Survodutide 2.4 mg - planned maintenance treatment.”
See source wording
under the skin · weekly
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)PHASE3 · NCT06077864
“survodutide 3.6 mg.”
See source wording
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightPHASE2 · NCT04667377
“0.6 mg BI 456906.”
See source wording
under the skin · weekly
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightPHASE3 · NCT06066515
“Survodutide 3.6 mg.”
See source wording
under the skin · weekly
Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseasePHASE2 · NCT07206290
“0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 3.6 mg s.c.”
See source wording
under the skin · weekly
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseasePHASE3 · NCT06176365
“Survodutide - 3.6 mg.”
See source wording
under the skin · weekly
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightPHASE3 · NCT06214741
“survodutide 3.6 mg.”
In animal studies
See source wording
rats · by mouth
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.Diabetes, obesity & metabolism · 2024
“In vivo potencies to engage the GLP-1R or GCGR were determined, measuring improvement in oral glucose tolerance (30 nmol/kg) and increase in plasma fibroblast growth factor-21 (FGF21) and liver nicotinamide N-methyltransferase (NNMT) mRNA expression (100 nmol/kg), respectively.”
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Study in people
Nature medicine · 2026
- Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Study in people
Hepatology (Baltimore, Md.) · 2026
- Survodutide Once Weekly for the Treatment of Adults with Obesity.
Study in people
The New England journal of medicine · 2026
- Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
Study in people
Diabetes, obesity & metabolism · 2026
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
Study in people
Diabetes, obesity & metabolism · 2026
- Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
Study in people
Diabetes, obesity & metabolism · 2026
- Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.
Study in people
Diabetes, obesity & metabolism · 2026
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).
Study in people
Obesity (Silver Spring, Md.) · 2025
- Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.
Study in people
Diabetes, obesity & metabolism · 2025
- Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
Study in people
Diabetes, obesity & metabolism · 2025
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Study in people
The lancet. Diabetes & endocrinology · 2024
- Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Study in people
Diabetologia · 2024
- Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.
Study in people
JACC. Heart failure · 2024
- Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
Animal study, rats or mice
Molecular metabolism · 2026
- Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.
Animal study, rats or mice
Diabetes, obesity & metabolism · 2026
- Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.
Animal study, rats or mice
Molecular metabolism · 2025
- The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Animal study, rats or mice
Diabetes, obesity & metabolism · 2024
- Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study.
Diabetes, obesity & metabolism · 2026
- Dual incretin agonist survodutide benefits in MASLD
Journal not recorded · 2026
- Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.
Cardiology in review · 2025
- Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.
Review of earlier work
Journal of translational medicine · 2026
- Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Review of earlier work
Endocrinology, diabetes & metabolism · 2026
- A review of survodutide: a new dual acting agonist.
Review of earlier work
Minerva endocrinology · 2026
- Phenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic Disorders
Review of earlier work
Journal not recorded · 2026
- Phenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic Disorders
Review of earlier work
Journal not recorded · 2026
- Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.
Review of earlier work
Journal of the American Heart Association · 2026
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Review of earlier work
Metabolism open · 2026
- How does survodutide work? Plain language review of a potential new medication for obesity and liver disease.
Review of earlier work
Therapeutic advances in gastroenterology · 2026
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
Review of earlier work
Cureus · 2026
- Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
Review of earlier work
The Journal of clinical investigation · 2025
- Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
Review of earlier work
Diabetes, obesity & metabolism · 2025
- Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.
Review of earlier work
Diabetology & metabolic syndrome · 2024